title: [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)].
abstract: We retrospectively analyzed the clinical course and prognosis of 11 patients with angioimmunoblastic T-cell Lymphoma (AILT). Median patient age was 62 years old (range 39 to 85). All patients were in clinical stage III or IV. Clinical features included B symptoms, hepatosplenomegaly, skin rushes, pleural effusion, ascites and polyclonal hypergammaglobulinemia. The disease can be classified into three categories based on histological findings: 3 cases of AILT with hyperplastic germinal centers, 4 cases of typical AILT, and 4 cases of AILT with numerous clear cells. As the initial therapy, 10 patients received combination chemotherapy and only 1 patient received autologous peripheral blood stem cell transplantation. Seven patients achieved CR and 4 showed PD. The response rate was 63% and the median survival time was 20 months. One patient survived in CR for 122 months. Patients with AILT demonstrating hyperplastic germinal centers and no bone marrow infiltration were able to achieve long-term survival. The survival time of AILT demonstrated a wide range. It was thought that further consideration of the prognostic factors and stratification was required.
authors.affiliation: Division of Internal Medicine, National Hospital Organization Nishigunma National Hospital.
authors.forename: Akio
authors.initials: A
authors.lastname: Saito
authors.forename: Yuri
authors.initials: Y
authors.lastname: Miyazawa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Isoda
authors.forename: Nahoko
authors.initials: N
authors.lastname: Hatsumi
authors.forename: Morio
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Masaru
authors.initials: M
authors.lastname: Kojima
authors.forename: Morio
authors.initials: M
authors.lastname: Sawamura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000145:classification / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016399:Lymphoma, T-Cell / Q000145:classification / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011379:Prognosis; D015996:Survival Rate